Cargando…
Evaluation of IScore validity in a Greek cohort of patients with type 2 diabetes
BACKGROUND: Diabetes constitutes a risk factor for stroke that also aggravates stroke prognosis. Several prognostic models have been developed for the evaluation of neurologic status, severity, short-term functional outcome and mortality of stroke patients. IScore is a novel tool recently developed...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3852226/ https://www.ncbi.nlm.nih.gov/pubmed/24041109 http://dx.doi.org/10.1186/1471-2377-13-121 |
_version_ | 1782478629285920768 |
---|---|
author | Dragoumanos, Vasileios Tzirogiannis, Konstantinos N Panoutsopoulos, Georgios I Krikonis, Konstantinos Fousteris, Evangelos Vourvou, Maria Elesnitsalis, Georgios Melas, Nikolaos Kourentzi, Kalliopi T Melidonis, Andreas |
author_facet | Dragoumanos, Vasileios Tzirogiannis, Konstantinos N Panoutsopoulos, Georgios I Krikonis, Konstantinos Fousteris, Evangelos Vourvou, Maria Elesnitsalis, Georgios Melas, Nikolaos Kourentzi, Kalliopi T Melidonis, Andreas |
author_sort | Dragoumanos, Vasileios |
collection | PubMed |
description | BACKGROUND: Diabetes constitutes a risk factor for stroke that also aggravates stroke prognosis. Several prognostic models have been developed for the evaluation of neurologic status, severity, short-term functional outcome and mortality of stroke patients. IScore is a novel tool recently developed in order to predict mortality rates within 30 days and 1 year after ischemic stroke and diabetes is not included in the scoring scale of IScore. The aim of the present study was to evaluate and compare IScore validity in ischemic stroke patients with and without diabetes. METHODS: This prospective study included 312 consecutive Caucasian patients with type 2 diabetes and 222 Caucasian patients without diabetes admitted for ischemic stroke in a tertiary Greek hospital. Thirty-day and 1-year IScores were individually calculated for each patient and actual mortality was monitored at the same time intervals. IScore’s predictive ability and calibration was evaluated and compared for ischemic stroke patients with and without diabetes. The performance of IScore for predicting 30 and 1-year mortality between patients with and without diabetes was assessed by determining the calibration and discrimination of the score. The area under the receiver operating characteristic curve was used to evaluate the discriminative ability of IScore for patients with and without diabetes, whereas the calibration of IScore was assessed by the Hosmer–Lemeshow goodness-of fit statistic. RESULTS: Baseline population characteristics and mortality rates did not differ significantly for both cohorts. IScore values were significantly higher for patients with diabetes at 30 days and 1 year after ischemic stroke and patients with diabetes presented more frequently with lacunar strokes. Based on ROC curves analysis IScore’s predictive ability for 30 day mortality was excellent, without statistically significant difference, for both cohorts. Predictive ability for 1 year mortality was also excellent for both groups with significantly better ability for patients with diabetes especially at high score values. Calibration of the model was good for both groups of patients. CONCLUSIONS: IScore accurately predicts mortality in acute ischemic stroke Caucasian patients with and without diabetes with higher efficacy in predicting 1 year mortality in patients with diabetes especially with high scores. |
format | Online Article Text |
id | pubmed-3852226 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-38522262013-12-06 Evaluation of IScore validity in a Greek cohort of patients with type 2 diabetes Dragoumanos, Vasileios Tzirogiannis, Konstantinos N Panoutsopoulos, Georgios I Krikonis, Konstantinos Fousteris, Evangelos Vourvou, Maria Elesnitsalis, Georgios Melas, Nikolaos Kourentzi, Kalliopi T Melidonis, Andreas BMC Neurol Research Article BACKGROUND: Diabetes constitutes a risk factor for stroke that also aggravates stroke prognosis. Several prognostic models have been developed for the evaluation of neurologic status, severity, short-term functional outcome and mortality of stroke patients. IScore is a novel tool recently developed in order to predict mortality rates within 30 days and 1 year after ischemic stroke and diabetes is not included in the scoring scale of IScore. The aim of the present study was to evaluate and compare IScore validity in ischemic stroke patients with and without diabetes. METHODS: This prospective study included 312 consecutive Caucasian patients with type 2 diabetes and 222 Caucasian patients without diabetes admitted for ischemic stroke in a tertiary Greek hospital. Thirty-day and 1-year IScores were individually calculated for each patient and actual mortality was monitored at the same time intervals. IScore’s predictive ability and calibration was evaluated and compared for ischemic stroke patients with and without diabetes. The performance of IScore for predicting 30 and 1-year mortality between patients with and without diabetes was assessed by determining the calibration and discrimination of the score. The area under the receiver operating characteristic curve was used to evaluate the discriminative ability of IScore for patients with and without diabetes, whereas the calibration of IScore was assessed by the Hosmer–Lemeshow goodness-of fit statistic. RESULTS: Baseline population characteristics and mortality rates did not differ significantly for both cohorts. IScore values were significantly higher for patients with diabetes at 30 days and 1 year after ischemic stroke and patients with diabetes presented more frequently with lacunar strokes. Based on ROC curves analysis IScore’s predictive ability for 30 day mortality was excellent, without statistically significant difference, for both cohorts. Predictive ability for 1 year mortality was also excellent for both groups with significantly better ability for patients with diabetes especially at high score values. Calibration of the model was good for both groups of patients. CONCLUSIONS: IScore accurately predicts mortality in acute ischemic stroke Caucasian patients with and without diabetes with higher efficacy in predicting 1 year mortality in patients with diabetes especially with high scores. BioMed Central 2013-09-16 /pmc/articles/PMC3852226/ /pubmed/24041109 http://dx.doi.org/10.1186/1471-2377-13-121 Text en Copyright © 2013 Dragoumanos et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Dragoumanos, Vasileios Tzirogiannis, Konstantinos N Panoutsopoulos, Georgios I Krikonis, Konstantinos Fousteris, Evangelos Vourvou, Maria Elesnitsalis, Georgios Melas, Nikolaos Kourentzi, Kalliopi T Melidonis, Andreas Evaluation of IScore validity in a Greek cohort of patients with type 2 diabetes |
title | Evaluation of IScore validity in a Greek cohort of patients with type 2 diabetes |
title_full | Evaluation of IScore validity in a Greek cohort of patients with type 2 diabetes |
title_fullStr | Evaluation of IScore validity in a Greek cohort of patients with type 2 diabetes |
title_full_unstemmed | Evaluation of IScore validity in a Greek cohort of patients with type 2 diabetes |
title_short | Evaluation of IScore validity in a Greek cohort of patients with type 2 diabetes |
title_sort | evaluation of iscore validity in a greek cohort of patients with type 2 diabetes |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3852226/ https://www.ncbi.nlm.nih.gov/pubmed/24041109 http://dx.doi.org/10.1186/1471-2377-13-121 |
work_keys_str_mv | AT dragoumanosvasileios evaluationofiscorevalidityinagreekcohortofpatientswithtype2diabetes AT tzirogianniskonstantinosn evaluationofiscorevalidityinagreekcohortofpatientswithtype2diabetes AT panoutsopoulosgeorgiosi evaluationofiscorevalidityinagreekcohortofpatientswithtype2diabetes AT krikoniskonstantinos evaluationofiscorevalidityinagreekcohortofpatientswithtype2diabetes AT fousterisevangelos evaluationofiscorevalidityinagreekcohortofpatientswithtype2diabetes AT vourvoumaria evaluationofiscorevalidityinagreekcohortofpatientswithtype2diabetes AT elesnitsalisgeorgios evaluationofiscorevalidityinagreekcohortofpatientswithtype2diabetes AT melasnikolaos evaluationofiscorevalidityinagreekcohortofpatientswithtype2diabetes AT kourentzikalliopit evaluationofiscorevalidityinagreekcohortofpatientswithtype2diabetes AT melidonisandreas evaluationofiscorevalidityinagreekcohortofpatientswithtype2diabetes |